Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Rectal Cancer
Interventions
DRUG

preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine

Therapy start: Capecitabine 1000mg/ m² bid during 14 days(d1-14), oxaliplatin 130mg/m² and Bevacizumab 7.5mg/kg body weight d1, repetition day 22 and 43 (3 cycles) Radiotherapy: Followed by 5 x 5 days 1.8 Gy after 1 week of concluded 3rd cycle of induction chemotherapy Chemotherapy: Capecitabine 825 mg/m2 bid (on each therapy day of first 4 therapy weeks)

Trial Locations (7)

1090

Medical University of Vienna, General Hospital, Vienna

4600

Klinikum Wels-Grieskirchen, Wels

5020

Paracelsus Medical University Salzburg - Oncology, Salzburg

6020

Medical University Innsbruck, Internal Medicine, Innsbruck

6807

State Hospital Feldkirch, Radiotherapy, Feldkirch

8036

Medical University Graz, Oncology, Graz

9330

Hospital BHB St. Veit/Glan, Surgery, Saint Veit A. D. Glan

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Austrian Breast & Colorectal Cancer Study Group

NETWORK

NCT01434147 - Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy | Biotech Hunter | Biotech Hunter